Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 136   

Articles published

NVO 55.35 +1.15 (2.12%)
price chart
Novo Nordisk A/S (ADR) (NYSE:NVO) close to 52-week high, short interest surging
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $56.27, up by 1.22%, with a volume of 1,155,117 shares against an average volume for the last 3 months of 1,713,340.
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...
Stocks giving huge returns to investors: Novo Nordisk A/S (ADR) (NYSE:NVO ...
Novo Nordisk A/S (ADR) (NYSE:NVO) was able to keep return on investment at 75.61% in the trailing twelve month while Reuters data showed that industry's average stands at 14.82% and sector's optimum level is 14.29%.
High Return on Assets Ratio for These Stocks: Novo Nordisk A/S (ADR) (NYSE:NVO ...
NetEase, Inc (ADR) (NASDAQ:NTES) has an ROA of 17.39%, maintained over the past 12 months. That number is higher than industry average, which is at 16.44% (as per Reuters data).
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Stocks with potential for strong ROE gains: Novo Nordisk A/S (ADR) (NYSE:NVO ...
Return on equity is one of the basic metrics used to evaluate a company's stock. It is the amount of net income returned as a percentage of shareholders equity.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
Stocks with potential for strong ROE gains: Novo Nordisk A/S (ADR) (NYSE:NVO ...
Novo Nordisk A/S (ADR) (NYSE:NVO) maintained return on equity for the last twelve months at 91.03%, higher than what Reuters data shows regarding industry's average.
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »